Development of a method for the sensitive and quantitative determination of hepcidin in human serum using LC-MS/MS

2009 ◽  
Vol 59 (3) ◽  
pp. 171-180 ◽  
Author(s):  
Hongyan Li ◽  
Mark J. Rose ◽  
Linh Tran ◽  
Jingwen Zhang ◽  
Les P. Miranda ◽  
...  
Keyword(s):  
Quantitative Determination ◽  
Human Serum

Quantitative determination of insulin-binding antibodies in human serum

1973 ◽  
Vol 45 (2) ◽  
pp. 145-151 ◽  
Author(s):  
Ljuben M. Sirakov ◽  
Stefan P. Ditzov
Keyword(s):  
Quantitative Determination ◽  
Human Serum ◽  
Insulin Binding

P0301FIT FOR PURPOSE VALIDATION OF A CLINICAL ASSAY FOR THE DETECTION OF SERUM LEVELS OF GALACTOSE-DEFICIENT IMMUNOGLOBULIN A1 (GD-IGA1) IN PATIENTS WITH IGA NEPHROPATHY (IGAN)

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Laura Sponton ◽  
Hulin Jin ◽  
Markus Fluck ◽  
Yusuke Suzuki ◽  
Amy Kao
Keyword(s):  
Quantitative Determination ◽  
Human Serum ◽  
Iga Nephropathy ◽  
Calibration Curve ◽  
Clinical Studies ◽  
Serum Samples ◽  
Freeze Thaw ◽  
Healthy Donors ◽  
Validation Parameters

Abstract Background and Aims Analysis of serum or plasma from patients with IgA nephropathy (IgAN) has confirmed the presence of elevated levels of circulating immune complexes containing Gd-IgA1 (Czerkinsky 1986). New sensitive and reasonably specific noninvasive tests are emerging to guide the therapeutic strategy that is applicable to all stages of IgAN (Suzuki 2014). Here we are reporting the fit for purpose validation of an ELISA method for the quantitative determination of Gd-IgA1 in human serum samples to support biomarker investigations in clinical studies of Merck KGaA, Darmstadt. Method The assay was developed based on a commercially available immunoassay kit. The dynamic range of the calibration curve was determined from 1.56 ng/mL (LLOQ) to 100 ng/mL (ULOQ). With a minimum required dilution of 200-fold and standard assay volume of 50.0 μL, the range of the method in matrix was from 312 ng/mL to 20, 000 ng/mL. In assay validation phase, multiple validation parameters were evaluated, which included minimum required dilution (MRD), calibration curve, matrix effect, Intra- & Inter run accuracy & precision, selectivity, and parallelism. Additional validation parameters include sample stability (short/long term, freeze-thaw) and batch-to-batch comparison. Results All samples measured for intra & Inter - assay precision, accuracy, fulfilled the specifications according to the acceptance criteria. The selectivity was assessed using blank serum matrix from 10 individuals: the result indicated that matrix components in serum did not interfere with the detection of Gd-IgA1. Parallelism assessment was performed successfully for both samples from healthy donors and IgAN patient samples up to dilution factor (DF) 3200 (serum samples from healthy donors were determined up to DF 1600). All DF-corrected results within the assay range were determined with %CV ≤ 30.0%. Batch to batch comparison was assessed successfully based on the known shelf life of the kit. Short term stability using QC samples were given for up to 24hrs at room temperature. Freeze-thaw stability was given for up to 3 cycles at -20°C±5°C and -75°C±15°C. The investigations were performed according to general guidelines for method validation and applicable regulations. The results of investigated validation parameters fulfilled the requirements and recommendations, generally accepted for bioanalytical projects. Conclusion The present validation qualified the method for the quantitative determination of Gd-IgA1 in human serum samples from clinical studies.

A paper-supported sandwich immunosensor based on upconversion luminescence resonance energy transfer for the visual and quantitative determination of a cancer biomarker in human serum

The Analyst ◽  
2020 ◽  
Vol 145 (12) ◽  
pp. 4181-4187 ◽  
Author(s):  
Mengyuan He ◽  
Ning Shang ◽  
Lin Shen ◽  
Zhihong Liu
Keyword(s):  
Energy Transfer ◽  
Quantitative Determination ◽  
Human Serum ◽  
Upconversion Luminescence ◽  
Resonance Energy Transfer ◽  
Resonance Energy ◽  
Cancer Biomarker

A portable and sensitive paper-supported sandwich immunosensor based on UC-FRET was developed for the visual and quantitative determination of CEA.

RP-LC Method for the Simultaneous Determination of Gliquidone, Pioglitazone Hydrochloride, and Atorvastatin in Formulations and Human Serum

2013 ◽  
Vol 96 (1) ◽  
pp. 56-59 ◽  
Author(s):  
Agha Zeeshan Mirza ◽  
M Saeed Arayne ◽  
Najma Sultana
Keyword(s):  
Phosphoric Acid ◽  
Quantitative Determination ◽  
Human Serum ◽  
Flow Rate ◽  
Drug Combination ◽  
Mobile Phase ◽  
Quantitative Method ◽  
Hplc Method ◽  
Established Method

Abstract The objective of this research was to develop and validate a rapid, economical, and sensitive HPLC method for quantitative determination of gliquidone, pioglitazone hydrochloride, and atorvastatin in tablets and serum. Due to drug combination of these formulations, there has been a need for a reliable quantitative method to determine these drugs in commercial samples and human serum. The chromatographic separation was carried out at ambient temperature with a mobile phase consisting of methanol–water (90 + 10, v/v), with pH adjusted to 3.50 with phosphoric acid. The pump was operated at a flow rate of 1 mL/min, and all analytes were detected at 235 nm. The method was linear over the concentration range of 5–50 μg/mL for all the drugs. The LOD of gliquidone, pioglitazone hydrochloride, and atorvastatin was 0.30, 1.30, and 0.57 μg/mL and LOQ was 0.98, 4.28, and 1.90 μg/mL, respectively. The proposed method was successfully applied to the determination of these drugs in commercial tablets and human serum. The established method was validated with respect to specificity, linearity, precision, accuracy, and ruggedness.

Sign in / Sign up

Export Citation Format

Share Document